Solara Active Pharma Sciences Limited
Healthcare›Healthcare›Pharmaceuticals & Biotechnology›Pharmaceuticals
Key metrics
Price as of 2026-07-17
Stock price
₹570.80
Market cap
2,541 Cr
P/B
2.02
Dividend yield
0.4%
Sign in for full ratios and TTM. Learn about these metrics →
Share price
NSE closing price from historical market data.
Loading price history…
Statement tables · Consolidated
Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.
Amounts in ₹ Cr · NSE preferred when both exchanges report the same period · tap + to expand rows
Quarterly results
Quarterly · ₹ Cr · tap + rows to expand
| Metric | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 352 Cr | 778 Cr | 1,026 Cr | 1,289 Cr | 363 Cr | 710 Cr | 300 Cr | 273 Cr | 319 Cr | 314 Cr | 349 Cr | 387 Cr |
| Operating expenses (approx.) | 331 Cr | 723 Cr | 1,196 Cr | 1,569 Cr | 321 Cr | 606 Cr | 243 Cr | 222 Cr | 261 Cr | 278 Cr | 318 Cr | 324 Cr |
| EBITDA | 21 Cr | 55 Cr | -169 Cr | -280 Cr | 42 Cr | 104 Cr | 58 Cr | 51 Cr | 58 Cr | 35 Cr | 31 Cr | 63 Cr |
| OPM % | 6.0% | 7.0% | -16.5% | -21.7% | 11.7% | 14.7% | 19.2% | 18.8% | 18.2% | 11.2% | 8.8% | 16.3% |
| Other income | 2 Cr | 3 Cr | 4 Cr | 5 Cr | 0.56 Cr | 0.88 Cr | 1 Cr | 6 Cr | 0.98 Cr | 0.49 Cr | 0.0000 Cr | 5 Cr |
| Interest | 25 Cr | 49 Cr | 74 Cr | 105 Cr | 31 Cr | 59 Cr | 27 Cr | 29 Cr | 24 Cr | 21 Cr | 22 Cr | 28 Cr |
| Depreciation | 26 Cr | 52 Cr | 78 Cr | 103 Cr | 25 Cr | 50 Cr | 25 Cr | 24 Cr | 24 Cr | 24 Cr | 26 Cr | 26 Cr |
| Profit before tax | -29 Cr | -46 Cr | -322 Cr | -488 Cr | -13 Cr | -5 Cr | 8 Cr | -2 Cr | 11 Cr | -10 Cr | -17 Cr | 10 Cr |
| Tax % | 34.9% | 22.1% | 3.2% | -16.1% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net profit | -19 Cr | -36 Cr | -312 Cr | -567 Cr | -13 Cr | -5 Cr | 8 Cr | -2 Cr | 11 Cr | -10 Cr | -17 Cr | 10 Cr |
| EPS (₹) | ₹-5.43 | ₹-10.20 | ₹-86.69 | ₹-157.62 | ₹-3.50 | ₹-0.96 | ₹2.03 | ₹-0.93 | ₹2.46 | ₹-2.36 | ₹-3.98 | ₹2.20 |
Profit & loss (annual)
Annual · last column is TTM · ₹ Cr · tap + to expand
| Metric | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,387 Cr | 1,322 Cr | 1,617 Cr | 1,268 Cr | 1,444 Cr | 1,289 Cr | 1,284 Cr | 1,369 Cr | Sign in for TTM |
| Operating expenses (approx.) | 1,153 Cr | 1,035 Cr | 1,202 Cr | 1,172 Cr | 1,310 Cr | 1,574 Cr | 1,069 Cr | 1,182 Cr | Sign in for TTM |
| EBITDA | 233 Cr | 287 Cr | 415 Cr | 97 Cr | 134 Cr | -285 Cr | 215 Cr | 187 Cr | Sign in for TTM |
| OPM % | 16.8% | 21.7% | 25.6% | 7.6% | 9.3% | -22.1% | 16.7% | 13.7% | Sign in for TTM |
| Other income | 12 Cr | 28 Cr | 29 Cr | 20 Cr | 23 Cr | 5 Cr | 8 Cr | 6 Cr | Sign in for TTM |
| Interest | 82 Cr | 78 Cr | 84 Cr | 75 Cr | 90 Cr | 105 Cr | 115 Cr | 95 Cr | Sign in for TTM |
| Depreciation | 83 Cr | 94 Cr | 109 Cr | 112 Cr | 111 Cr | 103 Cr | 99 Cr | 100 Cr | Sign in for TTM |
| Profit before tax | 68 Cr | 115 Cr | 222 Cr | -91 Cr | -45 Cr | -488 Cr | 0.54 Cr | -7 Cr | Sign in for TTM |
| Tax % | 0.9% | 0.3% | 0.1% | 36.0% | 50.4% | -16.1% | 0.0% | 0.0% | Sign in for TTM |
| Net profit | 59 Cr | 115 Cr | 221 Cr | -58 Cr | -22 Cr | -567 Cr | 0.54 Cr | -7 Cr | Sign in for TTM |
| EPS (₹) | ₹21.77 | ₹44.29 | ₹69.00 | ₹-16.18 | ₹-6.16 | ₹-157.62 | ₹0.14 | ₹-1.68 | Sign in for TTM |
| Dividend payout % | — | — | — | — | — | — | 0.0% | — | Sign in for TTM |
Sign in for TTM
Trailing twelve months totals and margin rows
Balance sheet
Annual · ₹ Cr · tap + rows to expand
| Metric | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 26 Cr | 27 Cr | 36 Cr | 36 Cr | 36 Cr | 36 Cr | 40 Cr | 45 Cr |
| Reserves | 934 Cr | 0.0000 Cr | 0.0000 Cr | 1,489 Cr | 1,464 Cr | 898 Cr | 1,057 Cr | 1,208 Cr |
| Borrowings | — | — | — | — | 1,001 Cr | 1,000 Cr | 662 Cr | 554 Cr |
| Other liabilities | — | — | — | — | 395 Cr | 414 Cr | 473 Cr | 523 Cr |
| Total liabilities | — | — | — | — | 2,899 Cr | 2,351 Cr | 2,232 Cr | 2,333 Cr |
| Fixed assets (net) | — | — | — | — | 921 Cr | 858 Cr | 739 Cr | 793 Cr |
| CWIP | — | — | — | — | 238 Cr | 256 Cr | 280 Cr | 205 Cr |
| Investments | — | — | — | — | 2 Cr | 2 Cr | 2 Cr | 5 Cr |
| Other assets | — | — | — | — | 1,220 Cr | 788 Cr | 729 Cr | 858 Cr |
| Total assets | — | — | — | — | 2,899 Cr | 2,351 Cr | 2,232 Cr | 2,333 Cr |
Cash flows
Annual · ₹ Cr · tap + rows to expand · last column includes FCF
| Metric | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Cash from operating activity | — | — | — | -242 Cr | 156 Cr | 109 Cr | 213 Cr | 153 Cr |
| Cash from investing | — | — | — | -243 Cr | -81 Cr | -4 Cr | -37 Cr | -99 Cr |
| Cash from financing | — | — | — | 334 Cr | -113 Cr | -106 Cr | -180 Cr | -54 Cr |
| Net cash flow | — | — | — | -151 Cr | -38 Cr | -0.29 Cr | -4 Cr | 0.53 Cr |
| Free cash flow (OCF − Capex) | — | — | — | -451 Cr | 45 Cr | 68 Cr | 173 Cr | 100 Cr |
Ratios
Ratios as reported or derived per annual period.
| Metric | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| ROCE % | 15.6% | 717.9% | 851.8% | -1.0% | 0.9% | -20.1% | 6.6% | 4.8% |
| ROE % | 6.2% | 0.0% | 0.0% | -3.8% | -1.5% | -60.6% | 0.0% | -0.6% |
| Debtor days | — | — | — | — | 135 | 99 | — | — |
| Inventory days | — | — | — | — | 262 | 173 | 199 | 172 |
| Days payable | — | — | — | — | 144 | 150 | — | — |
| Cash conversion cycle | — | — | — | — | 254 | 121 | 199 | 172 |
| Debt / equity | — | — | — | — | 0.67 | 1.07 | 0.60 | 0.44 |
| Current ratio | — | — | — | — | 1.08 | 0.63 | 0.77 | 0.96 |
| Net debt / EBITDA | 0.00 | 0.00 | 0.00 | 0.00 | 7.41 | — | 3.07 | 2.94 |
Compare with peers
Loading peers…